Report Highlights

Microbiome Sequencing Services in the U.S.: Market Overview

The U.S. accounts for roughly 40 percent of global microbiome sequencing service revenue, anchored by the density of academic medical centers, NIH-funded research and pharmaceutical R&D in Boston, San Diego, and the Research Triangle. Unlike the global market, which is weighted toward Asian contract research volume, U.S. demand is driven by clinical-grade stool and oral testing and by pharmaceutical trial endpoints. Buyers therefore evaluate providers on regulatory status rather than raw throughput.

The U.S. market is split between research-grade services sold to universities and biotech firms and a smaller but faster-growing clinical segment billed to payers and patients. Sequencing is typically outsourced, with most contract labs running Illumina and Oxford Nanopore platforms and delivering taxonomic profiles through cloud dashboards. Pricing remains fragmented, with 16S amplicon profiling commonly sold below USD 200 per sample and shotgun metagenomics between USD 300 and USD 600.

Growth Drivers in U.S. Microbiome Sequencing

First, FDA's November 2022 approval of Rebyota, the first fecal microbiota live biotherapeutic for recurrent Clostridioides difficile infection, validated microbiome-based clinical care in the U.S. market. Second, NIH continues to fund academic demand through the Human Microbiome Project legacy programs and multi-year grants for gut-brain and immuno-oncology studies administered by the National Institute of Allergy and Infectious Diseases.

Third, pharmaceutical sponsors running microbiome-modulating trials require standardized sequencing endpoints. Seres Therapeutics in Cambridge, Massachusetts and Vedanta Biosciences in Boston run late-stage programs that depend on contract sequencing data, sustaining steady procurement from certified providers across the Northeast and West Coast.

Market Restraints and Entry Barriers

CLIA certification under the Clinical Laboratory Improvement Amendments of 1988 is the central barrier, with CMS validation typically taking six to nine months for a new high-complexity laboratory. New York State adds separate approval through the Clinical Laboratory Evaluation Program, so any test reported to New York residents requires a second, independent review. Entrants without accredited laboratory directors face delays that compound across every assay they launch.

Incumbent advantage concentrates with Illumina, whose installed sequencing base and sample-prep kits such as Nextera Flex give established providers lower per-sample reagent costs. Data privacy adds further friction: HIPAA governs clinical specimens, and state genetic privacy laws in California and Illinois impose consent requirements. Reimbursement remains sparse, as most consumer tests are self-pay, which limits volume predictability for new entrants.

Market Opportunities in the U.S.

The clearest near-term opening is clinical 16S and shotgun profiling for hospital laboratories and oncology centers, a segment we estimate at USD 210 million in 2024 within the USD 1.38 billion national market. Regional hospital networks in the Midwest, which lack in-house sequencing capacity, offer under-served demand that contract labs can capture through hub-and-spoke service models.

Pharmaceutical trial sequencing presents a second opportunity, with more than 60 microbiome-related clinical trials registered on ClinicalTrials.gov requiring standardized endpoint analysis. Agricultural and animal health testing, centered on livestock operations in Iowa and Nebraska, adds a smaller but less regulated channel with faster time to revenue for providers already holding research-use-only capabilities.

Market at a Glance

Leading Market Participants

• Illumina
• Thermo Fisher Scientific
• Pacific Biosciences
• Oxford Nanopore Technologies
• Azenta Life Sciences
• Novogene
• Zymo Research
• Psomagen
• Diversigen
• Viome

Regulatory and Policy Environment

The Clinical Laboratory Improvement Amendments of 1988 are administered by CMS, and providers offering clinical reporting must hold CLIA certificates. FDA's Laboratory Developed Tests rule, finalized in May 2024, was vacated by the U.S. District Court for the Eastern District of Texas in March 2025, leaving laboratory oversight primarily with CMS. New York State requires separate CLEP approval, a process generally taking four to six months, while research-use-only kits fall under FDA oversight of the Federal Food, Drug, and Cosmetic Act.

NIH funds microbiome research through grant programs administered by institutes including NIAID, within an agency budget exceeding USD 47 billion in fiscal 2024. Data governance follows HIPAA administered by HHS, the Common Rule for human-subject studies, and state genetic privacy statutes such as California's Genetic Information Privacy Act. Entrants should budget 12 to 18 months for full compliance readiness before commercial launch.

Long-Term Outlook for U.S. Microbiome Sequencing

By 2032 the U.S. market is projected to reach USD 3.46 billion, with clinical-grade services commanding a larger share as CLIA-certified capacity consolidates. Expect fewer but larger contract laboratories, with mid-sized providers acquired by platform vendors and diagnostic groups seeking microbiome panels for oncology and metabolic disease.

Growth will be most durable where sequencing becomes embedded in drug development and clinical decision-making rather than consumer curiosity. Providers that secure reimbursement pathways and multi-state licensure by 2028 will hold defensible positions, while sub-scale research-only laboratories face margin compression as sequencing prices continue to decline.